News

Avella Newsroom

January 1, 1970|
Managing Patients with IBD with Biologics
May 1, 2018| CATEGORIES: Press Mention

At Asembia Specialty Pharmacy Summit 2018, Kelly Mathews, PharmD, CSP, the director of clinical services and residency program director at Avella Specialty Pharmacy, discusses the paradigm shift in treating patients with inflammatory bowel disease with Christopher T. Owens, PharmD, MPH, the associate vice president, Kasiska Division of Health Sciences, Idaho State University. 

Avella Selected by Otsuka to distribute JYNARQUE
April 27, 2018| CATEGORIES: Press Release

The specialty pharmacy will give patients access to this new therapy for polycystic kidney disease, the only FDA-approved drug available in the US to treat this condition.

Phoenix, AZ -- Avella announced that it has been selected by Otsuka America Pharmaceutical, Inc. (Otsuka) to distribute JYNARQUE™ (tolvaptan), the very first FDA-approved therapy for patients diagnosed with autosomal dominant polycystic kidney disease (ADPKD). Avella is one of just three pharmacies providing access to the medication.

Avella Releases New Report on Anticipated Specialty Drug Approvals
April 27, 2018| CATEGORIES: Specialty Pharmacy , Press Release , limited distribution drugs

The leading specialty pharmacy has compiled insights about the specialty drug pipeline along with an analysis of the network distribution strategies for these medications.

Phoenix, AZ -- Avella has just announced the release of a 16-page report detailing the specialty drug pipeline, including all of the latest medications expected to receive FDA approval within the coming months. The 2018 Q2 Specialty Medication Pipeline Report provides at-a-glance information about all of these therapies including indications, approval status, anticipated costs, clinical considerations and therapeutic alternatives, among other key data points. It also provides helpful explanations of the various designations and approval processes undertaken by the FDA for specific types of medication such as orphan drugs and breakthrough therapies.

Avella to Improve Access to Naloxone, an Opioid Overdose-Reversing Medication, Through an Innovative New Program
April 24, 2018| CATEGORIES: Press Release , Pain Management , Addiction Management

The program’s launch will help further the Surgeon General’s efforts to encourage Americans
to carry this drug and help save lives.

Phoenix, AZ -- Avella has announced it will distribute naloxone, a powerful therapy used to treat opioid overdoses, as part of an innovative new program designed to improve access to the drug. The program allows individuals and family members in certain states to simply contact the pharmacy and order the drug by phone, with no physician prescription needed. In these circumstances, one of Avella’s pharmacists will actually supply the prescription if they determine that EVZIO® (naloxone HCl injection) or another naloxone therapy is appropriate. 

NCPDP Annual Conference Keynote Panel to Address “Data Challenges and Opportunities to Improve the Patient Journey”
April 17, 2018| CATEGORIES: Avella , Specialty Pharmacy , Press Mention

NCPDP announced today the Opening Keynote Panel for its 2018 Annual Technology & Business Conference, Industry United to Improve the Patient Journey, May 7-9, 2018, at the Westin Kierland Resort & Spa in Scottsdale, Arizona. The Keynote Panel will address “Data Challenges and Opportunities to Improve the Patient Journey,” on Tuesday, May 8, 2018. Avella founder and chairman of the board, John Musil, will participate on the panel representing specialty pharmacy.

LD Networks Shrinking; What Do You Need to Get In?
April 2, 2018| CATEGORIES: Specialty Pharmacy , Press Feature , limited distribution drugs

Many of today’s most effective specialty drugs are distributed through limited networks of specialty pharmacies, ranging in size from exclusive (one to two pharmacies) through limited small (two to five pharmacies) and limited large (six to 15 pharmacies). A new white paper from Avella Specialty Pharmacy reports that with 79.2% of manufacturers managing their specialty products through a limited distribution (LD) model, these LDs are shrinking even more, consisting of fewer pharmacies than they did just a decade ago.

The Leukemia & Lymphoma Society (LLS) Names Avella Executive Hamilton Baiden as the Corporate Walk Chair for Greater Phoenix Light The Night
March 29, 2018| CATEGORIES: Avella , Oncology , LLS , Press Release

Phoenix, AZ – The Arizona Chapter of The Leukemia & Lymphoma Society (LLS) announced today that Avella Specialty Pharmacy Executive Vice President Hamilton Baiden will serve as the Corporate Walk Chair of the 2018 Greater Phoenix Light The Night.

Improving medication adherence — something’s got to give
January 25, 2018| CATEGORIES: Adherence , Press Mention

Avella was recently featured in Pharmaceutical Commerce article for its work in medication adherence and technology. 

Poor adherence to prescribed medications creates one of today’s most pressing public health issues. When patients fail to take their medications as prescribed — either stopping before the course of treatment is complete, abandoning long-term therapies prescribed for chronic conditions, or taking the medications incorrectly — it creates far-reaching clinical and financial consequences for all stakeholders:

Abby Kaplan is Avella Specialty Pharmacy's Master of Acquisition
December 26, 2017| CATEGORIES: Avella , Press Feature

There are two main ways to expand a company,” says Avella Specialty Pharmacy’s Abby Kaplan. “You can do it organically, or you can do it through acquisition.” In 2016, Avella did both.

Controversy Heats Up Over Pharmacy Benefit Manager DIR fees
November 10, 2017| CATEGORIES: Press Mention , DIR Fees

Pharmacy benefits managers (PBMs) are in hot water again if small and specialty pharmacies’ voices can be heard. Besides a litany of complaints from various pharmacy industry stakeholders about PBM operations and business tactics—from a lack of transparency to controlling formularies—now PBMs are being accused of retroactively applying direct and indirect remuneration fees (DIR) to pharmacies.

News Alerts
If you would like to receive email updates from Avella Specialty Pharmacy, please complete the information below.
Subscribe
Featured Video
Photo of Brian Halligan
Path of a Specialty Prescription
The path of a specialty prescription is complex. This video details each step of the path and the unique offerings of Avella.
Media Contact

Sarah McLeod
800-516-2881  x103
smcleod@activate-health.com

Avella is available to coordinate subject matter expert interviews on a variety of topics including.

  • Specialty pharmacy/pharmacist role
  • Medication adherence and technology
  • Specialty pharmacy pricing considerations

Please contact Sarah McLeod for more information about Avella Specialty Pharmacy.

News Alerts
If you would like to receive email updates from Avella Specialty Pharmacy, please complete the information below.
Subscribe